SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Szarek M)
 

Sökning: WFRF:(Szarek M) > Effects of alirocum...

Effects of alirocumab on types of myocardial infarction: Insights from the ODYSSEY OUTCOMES trial

White, H.D. (författare)
Green Lane Cardiovascular Services, Auckland City Hospital, 5 Park Road, Grafton, Auckland, 1142, New Zealand
Gabriel, Steg Ph. (författare)
FACT (French Alliance for Cardiovascular Trials), F-CRIN network, Département Hospitalo-Universitaire FIRE, AP-HP, Hôpital Bichat, Université Paris-Diderot, Sorbonne Paris-Cité, INSERM U-1148, 46 rue Henri Huchard, Paris, 75018, France; National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, Sydney Street, London, SW3 6NP, United Kingdom
Szarek, M. (författare)
Department of Epidemiology and Biostatistics, SUNY Downstate Medical Center School of Public Health, 450 Clarkson Avenue, Brooklyn, NY 11203, United States
visa fler...
Bhatt, D.L. (författare)
Brigham and Women’s Hospital Heart and Vascular Center, Harvard Medical School, 75 Francis Street, Boston, MA 02115, United States
Bittner, V.A. (författare)
Division of Cardiovascular Disease, University of Alabama at Birmingham, 701 19th Street South - LHRB 310, Birmingham, AL 35294, United States
Diaz, R. (författare)
Estudios Cardiológicos Latinoamérica, Instituto Cardiovascular de Rosario, Paraguay 160, Rosario, Santa Fe, Argentina,Duke Clinical Research Institute, 200 Morris Street, Durham, NC 27710, United States
Edelberg, J.M. (författare)
Sanofi, 55 Corporate Drive, Bridgewater, NJ 08807, United States
Erglis, A. (författare)
Latvian Centre of Cardiology, Pauls Stradins Clinical University Hospital, University of Latvia, Pilsonu Street 13, Riga, LV1002, Latvia
Goodman, S.G. (författare)
Canadian VIGOUR Centre, 2-132 Li Ka Shing Centre for Health Research Innovation, University of Alberta, Edmonton, AB T6G 2E1, Canada; St. Michael’s Hospital, University of Toronto, 30 Bond Street, Toronto, ON M5B 1W8, Canada,Division of Cardiology, University of Colorado School of Medicine, 1700 N. Wheeling Street, Aurora, CO 80045, United States
Hanotin, C. (författare)
Sanofi, 54-56 Rue la Boétie, Paris, 75008, France
Harrington, R.A. (författare)
Stanford Center for Clinical Research, Department of Medicine, 300 Pasteur Drive, S-102, Stanford, CA 94305, United States
Wouter, Jukema J. (författare)
Department of Cardiology, Leiden University Medical Center, 2300 RC, Leiden, Netherlands
Lopes, R.D. (författare)
Duke Clinical Research Institute, 200 Morris Street, Durham, NC 27710, United States
Mahaffey, K.W. (författare)
Department of Medicine, Stanford University School of Medicine, 300 Pasteur Drive, Grant S-102, Stanford, CA 94305, United States
Moryusef, A. (författare)
Sanofi, 55 Corporate Drive, Bridgewater, NJ 08807, United States,Department of Medicine III, Goethe University, Theodor-Stern-Kai 7, Frankfurt am Main, 60590, Germany
Pordy, R. (författare)
Regeneron Pharmaceuticals, 777 Old Saw Mill River Road, Tarrytown, NY 10591, United States
Roe, M.T. (författare)
Duke Clinical Research Institute, 200 Morris Street, Durham, NC 27710, United States
Sritara, P. (författare)
Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Rama VI Road10400, Thailand
Tricoci, P. (författare)
CSL Behring, 1100 N Miami Blvd Ste 613, Durham, NC 27703, United States
Zeiher, A.M. (författare)
Department of Medicine III, Goethe University, Theodor-Stern-Kai 7, Frankfurt am Main, 60590, Germany
Schwartz, G.G. (författare)
Division of Cardiology, University of Colorado School of Medicine, 1700 N. Wheeling Street, Aurora, CO 80045, United States
ODYSSEY, OUTCOMES Investigators (författare)
Olsson, Anders, 1940- (bidragsgivare)
Linköpings universitet,Avdelningen för kardiovaskulär medicin,Medicinska fakulteten,Region Östergötland, Endokrinmedicinska kliniken,ODYSSEY OUTCOMES Investigators
Hagström, Emil (författare)
Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi
Ball, Eric (författare)
visa färre...
 (creator_code:org_t)
2019-05-23
2019
Engelska.
Ingår i: European Heart Journal. - : Oxford University Press. - 0195-668X .- 1522-9645. ; 40:33, s. 2801-2809
Relaterad länk:
https://liu.diva-por... (primary) (Raw object)
visa fler...
https://academic.oup...
https://doi.org/10.1...
https://uu.diva-port... (primary) (Raw object)
https://urn.kb.se/re...
https://doi.org/10.1...
https://urn.kb.se/re...
http://kipublication...
visa färre...
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Aims The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin–kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (=1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI. Methods and results Median follow-up was 2.8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860 total MIs, 1223 (65.8%) were adjudicated as Type 1, 386 (20.8%) as Type 2, and 244 (13.1%) as Type 4. Few events were Type 3 (n = 2) or Type 5 (n = 5). Alirocumab reduced first MIs [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77–0.95; P = 0.003], with reductions in both Type 1 (HR 0.87, 95% CI 0.77–0.99; P = 0.032) and Type 2 (0.77, 0.61–0.97; P = 0.025), but not Type 4 MI. © The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kardiologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)

Nyckelord

Alirocumab

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy